Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Nerandomilast - JASCAYD official label
Product / population
Nerandomilast - JASCAYD official label; selected source sections, not a full prescribing monograph.
Renal method
eGFR, mL/min/1.73 m2; retain body-surface-area indexing. CKD-EPI is named.
Source revision
Prescribing information revised 08/2026.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
JASCAYD: official guidance does not repair the RX rendering
The RX card is PK-only. The August 2026 official label separately supplies renal prescribing guidance and an ESRD restriction.
What to reconcile: Use the official section for prescribing scope while keeping the incomplete RX source flagged; neither is an independent validation of the same label.
DailyMed / Boehringer Ingelheim Pharmaceuticals, Inc. · Nerandomilast - JASCAYD official label; selected source sections, not a full prescribing monograph.
Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing. CKD-EPI is named. Source date: Prescribing information revised 08/2026. Retrieved: 2026-09-08
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Section 8.6 recommends the same dosage as normal renal function for mild (eGFR >=60 to <90), moderate (>=30 to <60) and severe (>=15 to <30) impairment, in mL/min/1.73 m2 with CKD-EPI specified. ESRD below 15 has not been investigated and use is not recommended. This selected renal guidance does not replace the product dosage, tolerability, interaction or indication instructions. It is separate official-label content, not an additional independent clinical study.
RDM48-official-nerandomilast-jascayd-cdf5d3150c-C1 · Source locator: Prescribing information 8.6; 12.3; revision in highlights.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.